- Home
- Drug And Medication Industry
- Novartis Market and Forecasts, May 2012
Industries
- Drug and Medication (149)
- Pathology (107)
- Drug Discovery and Development (94)
- Business Services (70)
- Metal and Mineral (24)
-
- Biopharmaceutical (22)
- Healthcare (22)
- Pharmaceutical (22)
- Oil and Gas Energy (16)
- Investment Banking (13)
- Biotechnology (12)
- Energy & Environment (12)
- Blood Supply, Tissue Banking and Transplantation (11)
- Pension (10)
- Drug Delivery Technology (9)
- Education and Training (9)
- Biological Therapy (8)
- Building Material (8)
- Hotel and Lodging (8)
- Insurance (8)
Top countries
- United States (430)
- World (135)
- India (109)
- Europe (72)
- Switzerland (63)
-
- China (49)
- Canada (42)
- United Kingdom (35)
- France (27)
- Russian Federation (27)
- Japan (24)
- Australia (24)
- Germany (23)
- Pakistan (12)
- Singapore (12)
- South Korea (12)
- Ireland (9)
- Luxembourg (8)
- Netherlands (8)
- Israel (7)
Publication dates
All regions
-
- Austria (2)
- Belarus (1)
- Belgium (3)
- Bulgaria (2)
- Czech Republic (1)
- Denmark (4)
- Estonia (1)
- Finland (4)
- France (27)
- Germany (23)
- Greece (5)
- Ireland (9)
- Italy (7)
- Liechtenstein (1)
- Luxembourg (8)
- Netherlands (8)
- Norway (3)
- Poland (5)
- Romania (1)
- Russian Federation (27)
- Slovakia (slovak Republic) (2)
- Slovenia (2)
- Spain (7)
- Sweden (1)
- Switzerland (63)
- Ukraine (6)
- United Kingdom (35)
-
- Australia (24)
- Austria (2)
- Belgium (3)
- Canada (42)
- Chile (1)
- Czech Republic (1)
- Denmark (4)
- Estonia (1)
- Finland (4)
- France (27)
- Germany (23)
- Greece (5)
- Ireland (9)
- Israel (7)
- Italy (7)
- Japan (24)
- Luxembourg (8)
- Mexico (1)
- Netherlands (8)
- Norway (3)
- Poland (5)
- Slovakia (2)
- Slovenia (2)
- South Korea (12)
- Spain (7)
- Sweden (1)
- Switzerland (63)
- Turkey (7)
- United Kingdom (35)
- United States (430)
Novartis Market and Forecasts, May 2012
You might be interested in: clinical trial, drug, vaccine, more »
industry reports
Novartis Inc. - Annual Report 2011
- Company report
- March 2011
- 47 pages
- by Corporation
... Vildagliptin) received eu approval for expanded use as a second line monotherapy for type 2 diabetes patients who cannot take metformin. In china, novartis received regulatory approval for lucentis ...
- Industries: Pathology
- Countries: United States
Novartis Inc. - Investment Analysis, March 2011
- Company report
- March 2011
- 3 pages
... Dr. Dimitri azar elected as new member of the novartis board of directors for a three year term Drs. Srikant datar, andreas von planta and wendelin wiedeking re-elected for three-year term each ...
- Industries: General Medicine and Specialty Medicine
- Countries: United States
Novartis Inc. - Company Report for Year 2012
- Company report
- January 2012
- 4 pages
- by Corporation
... Citizen. 6. Appointment of the auditor the board of directors proposes the election of pricewaterhousecoopers ag as auditor of novartis ag for one year. For the board of directors the chairman ...
- Industries: Telephony
- Countries: United States
Novartis India Ltd. - Investment Analysis, September 2011
- Company report
- September 2011
- 7 pages
- by Corporation
... Of the swiss pharmaceutical major novartis ag. Nil is one of india S leading manufactus and marketers of pharmaceuticals, over-the-counter (otc) products, as well as of nutrition, eye care and animal ...
- Industries: Veterinary Healthcare
- Countries: India
The United States and Switzerland: Country Brief, 2012-2013, focus on General Medicine and Specialty Medicine
- Country report
- January 2012
- 3 pages
... Potential of rasilez/tekturna leads to an exceptional charge of approximately usd 900 million in fourth quarter 2011 In addition, as part of ongoing portfolio review, novartis to take an exceptional ...
- Industries: General Medicine and Specialty Medicine
- Countries: United States, Switzerland, World
Investor presentation: Pathology for Year 2011
- Company report
- March 2011
- 79 pages
... Actual results may vary materially from those described herein as anticipated, believed, estimated or expected. novartis is providing the information in this presentation as of this date and does ...
- Industries: Pathology
Investor presentation: Pathology for Year 2011
- Company report
- October 2011
- 47 pages
- by Corporation
... Will achieve any particular revenue levels. Nor can there be any guarantee that novartis will be able to realize any of the potential synergies, strategic benefits or opportunities as a result of the merger ...
- Industries: Pathology
Idenix Pharmaceuticals Inc. - Company Report for Year 2011
- Company report
- December 2011
- 212 pages
... And officers and novartis pharma ag to be affiliates. The number of shares outstanding of the registrant S class of common stock as of february 21, 2012 was 107,592,574 shares. Documents incorporated ...
- Industries: Drug Discovery and Development
- Countries: United States
Investor presentation: Business Services in The United States for Year 2011
- Company report
- September 2011
- 21 pages
- by Corporation
... Capabilities within the network Exit of declining specialty lens business increase productivity resource allocation productivity 2 13 | novartis strategy and innovation forum ii | jonathan symonds ...
- Industries: Business Services
- Countries: United States
Emisphere Technologies Inc. - Company Report for Year 2011
- Company report
- December 2011
- 246 pages
... Ct ) In the treatment of osteoarthritis of the knee, novartis informed emisphere that it has reviewed the first interpretable results and advised emisphere of its top line conclusions as follows: preliminary analysis ...
- Industries: Drug and Medication
- Countries: United States
Reportlinker.com © Copyright 2012. All rights reserved
